ANJI PHARMA
Bridging the Type-2 Diabetes Treatment Gap
Metformin Doesn’t Work for Everyone
Metformin, the go-to treatment to manage high blood sugar in patients with Type-2 Diabetes, can’t be used safely by patients who also suffer from Chronic Kidney Disease (CKD).
Anji Pharma is currently developing ANJ900 (Metformin DR), whose primary site of action is the gut. This approach minimizes metformin absorption and offers a safer option for patients with advanced CKD.
Showing the Difference Between Metformin and ANJ900
We teamed up with MacDougall Advisors to help tell the story of how ANJ900 better serves this patient group.
We developed an engaging 3D animation that follows the journey ANJ900 takes through the body, showing the benefits of their timed-release capsule.
The animation needed to highlight key points of anatomy, and accurately reflect Anji Pharma’s newly established visual identity, while expanding upon it to develop new standards for the way they will represent 3D animated scenes in the future.
Style Frames
Final Result
The animation we produced successfully addresses both patient and provider audiences, and showcases the benefits ANJ900 possesses for this currently underserved patient group.
Let’s Get Started.
Want to discuss your next project, or just get some further information? We'd love to chat.